Physician profile
Anang Modi
NPI 1790724557
$479,255.31
in general payments reported to CMS, 2019-2025
44 companies · $87K in 2025
The $87K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $99K · 2020: $53K · 2021: $56K · 2022: $70K · 2023: $47K · 2024: $67K · 2025: $87K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $182K · Food and Beverage: $15K · Travel and Lodging: $2,892 · Education: $299 · Consulting Fee: $295.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $182,387.25 |
| Food and Beverage | $15,173.22 |
| Travel and Lodging | $2,891.96 |
| Education | $298.98 |
| Consulting Fee | $295.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $185,362.05 | 2019-2025 | |
| Janssen Biotech, INC. | $63,089.35 | 2019-2025 | Simponi Aria, Tremfya |
| Mallinckrodt Hospital Products INC. | $48,102.56 | 2020-2025 | Acthar |
| Amgen INC. | $41,051.48 | 2019-2025 | Otezla, Otezla, Evenity |
| Janssen Scientific Affairs, LLC | $30,474.77 | 2020-2023 | Simponi Aria, Stelara, Tremfya |
| Horizon Therapeutics Plc | $27,489.97 | 2019-2023 | Krystexxa |
| E.R. Squibb & Sons, L.L.C. | $20,101.21 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $18,617.50 | 2019-2021 | |
| Celgene Corporation | $16,471.79 | 2019 | |
| Mallinckrodt Enterprises LLC | $13,524.20 | 2019 | |
| Ucb, INC. | $7,608.89 | 2019-2025 | Bimzelx, Cimzia |
| Genzyme Corporation | $2,283.13 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $1,681.72 | 2019-2025 | |
| Pfizer INC. | $897.83 | 2019-2024 | |
| Astrazeneca Pharmaceuticals Lp | $522.36 | 2021-2025 | Saphnelo |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anang Modi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.